Table 3.
Univariate and multivariate analyses for worse cancer-specific survival. AHNAK2, T stage, N stage, grade, LVI, and CIS were evaluated, and statistically significant values are highlighted in bold.
| Variable | Category | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | p-Value | HR | 95% CI | p-Value | ||
| AHNAK2 | HE | 1.91 | 1.08–3.38 | 0.023 | 2.22 | 1.14–4.31 | 0.019 |
| LE | 1.0 | 1.0 | |||||
| T stage | MIBC | 2.01 | 0.98–4.13 | 0.057 | 1.44 | 0.50–4.11 | 0.68 |
| NMIBC | 1.0 | 1.0 | |||||
| N stage | ≥pN1 | 3.03 | 1.69–5.45 | <0.001 | 1.19 | 1.25–4.97 | 0.009 |
| pN0 | 1.0 | 1.0 | |||||
| Grade | G3 | 1.65 | 0.87–3.15 | 0.13 | 1.17 | 0.54–2.56 | 0.69 |
| G1/2 | 1.0 | 1.0 | |||||
| LVI | Positive | 2.43 | 1.23–4.80 | 0.01 | 1.19 | 0.53–2.64 | 0.68 |
| Negative | 1.0 | 1.0 | |||||
| CIS | Positive | 0.42 | 0.15–1.18 | 0.101 | 0.57 | 0.17–1.91 | 0.37 |
| Negative | 1.0 | 1.0 | |||||
HR, hazard ratio; CI, confidence interval; HE, high expression; LE, low expression; MIBC, muscle-invasive bladder cancer; NMIBC, nonmuscle-invasive bladder cancer; LVI, lymphovascular invasion; CIS, carcinoma in situ.